Compare ARK Fintech Innovation ETF (ARKF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ARK Fintech Innovation ETF trades at $42.7, while State Street SPDR S&P Biotech ETF trades at $159.19. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $58.82 | $164.28 |
52-Week Low | $36.14 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.70, down 0.93% today amid a broader fintech and crypto sector consolidation. The ETF's technical outlook is bullish based on moving averages, but oscillators are neutral with an overbought short-term RSI. Recent underperformance includes a 23% decline since July 2025, lagging the S&P 500 by 45 percentage points, with elevated volatility at 33.6%.
Outlook remains cautious due to high valuation multiples and sector headwinds. Risks include stretched P/E of 33x and PEG of 2.0x, signaling potential overvaluation. Investor sentiment is mixed, with a Hold rating reflecting fair valuation concerns amid ongoing consolidation pressures.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
